VE-PTP Extracellular Domain Antibodies Delivered by a Gene Therapy Vector
The disclosure provides compositions and methods for the treatment of ocular conditions associated with angiogenesis, comprising administering a nucleic acid that encodes for a tyrosine phosphatase suppressor to a subject.
1 . A pharmaceutical composition comprising a nucleic acid, wherein the nucleic acid is carried by a vector, wherein the nucleic acid encodes a tyrosine phosphatase suppressor.
2 . The pharmaceutical composition of claim 1 , wherein the tyrosine phosphatase is HPTPβ.
3 . The pharmaceutical composition of claim 1 , wherein the tyrosine phosphatase suppressor is a monoclonal antibody or an antigen-binding fragment thereof.
4 . The pharmaceutical composition of claim 1 , wherein the vector is a viral vector.
5 . The pharmaceutical composition of claim 4 , wherein the viral vector is an adenovirus-associated viral vector.
6 . The pharmaceutical composition of claim 1 , wherein the tyrosine phosphatase suppressor binds an extracellular domain of HPTPβ.
7 - 27 . (canceled)
28 . An antibody comprising:
a) a heavy chain variable region that comprises i) a sequence that has at least 90% homology to SEQ ID NO: 1; and ii) a human immunoglobulin sequence; and
b) a light chain.
29 . The antibody of claim 28 , wherein the immunoglobulin sequence is human IgG.
30 . The antibody of claim 28 , wherein the immunoglobulin sequence is human IgG4.
31 . The antibody of claim 28 , wherein the antibody is a HPTPβ suppressor.
32 . A pharmaceutical composition comprising an antibody comprising:
a) a heavy chain variable region that comprises i) a sequence that has at least 90% homology to SEQ ID NO: 1; and ii) a human immunoglobulin sequence; and
b) a light chain.
33 . A method for treating a condition in a human in need thereof, the method comprising administering to the human a therapeutically-effective amount of a pharmaceutical composition comprising an antibody comprising:
a) a heavy chain variable region that comprises i) a sequence that has at least 90% homology to SEQ ID NO: 1; and ii) a human immunoglobulin sequence; and
b) a light chain.
34 . The method of claim 33 , wherein the condition is an ocular condition.
35 . The method of claim 33 , wherein treating the condition comprises reducing neovascularization in an eye.
36 . The method of claim 33 , wherein treating the condition comprises reducing vascular leak in an eye.
37 . The method of claim 33 , wherein treating the condition comprises increasing vascular stability in an eye.
38 . The method of claim 33 , wherein the condition is a wet age-related macular degeneration.
39 . The method of claim 33 , wherein the condition is retinal vein occlusion.
40 . The method of claim 33 , wherein the condition is diabetic macular edema.
41 . The method of claim 33 , wherein the composition is administered by intraocular injection.